Corporate Governance27 Jul 2026, 06:00 pm
Senores Pharma: No Deviation in Preferential Issue Fund Utilization
AI Summary
Senores Pharmaceuticals Limited has submitted a statement of deviation or variation in the utilization of funds raised through a preferential issue of 11,70,000 convertible equity warrants. The funds were raised on March 28, 2026, amounting to ₹95,00,40,000. For the quarter ended June 30, 2026, the company confirms there has been no deviation from the stated objects, which included funding working capital, product development, investment in subsidiaries, and general corporate purposes. The statement was reviewed by the Audit Committee and taken on record by the Board of Directors on July 27, 2026.
Key Highlights
- Senores Pharma confirms no deviation in preferential issue fund utilization for Q2 FY26.
- Funds raised via convertible warrants totaled ₹95 Cr.
- Utilization covered working capital, product development, and subsidiaries.
- Audit Committee and Board of Directors have reviewed and approved the statement.
- No deviation reported for the period ending June 30, 2026.
Price Impact
More from SENORES